[Alzheimer's Drug Discovery Foundation](https://www.alzdiscovery.org)

September 14, 2026: Letter of Intent deadline

Up to $600,000 for one year; potential for follow-on funding

Supports development and validation of innovative biomarkers for Alzheimer’s and related dementias with strong clinical and commercial potential.

Only direct costs allowed; open to global academic, nonprofit, and biotech applicants.

--- ## Description This opportunity funds the development and validation of established and novel biomarkers that address critical clinical needs in Alzheimer’s disease and related dementias. The focus is on biomarkers with a defined context of use, clear advantages over existing options, and a credible path to commercialization or clinical adoption. High-priority areas include neuroinflammation, synaptic integrity, autophagy, TDP-43, neuronal loss, vascular injury, mitochondrial function, protein misfolding, oxidative stress, white matter changes, Lewy body dementia, and other novel targets with strong biological rationale. Supported modalities include PET ligands, CSF biomarkers, MRI, and advanced EEG approaches. Projects must demonstrate clinical utility, innovation, and translational potential. --- ## Due Dates - September 14, 2026: Letter of Intent deadline _All dates are projected based on the annual cycle; check the program page for updates._ --- ## Funding Amount - Maximum award: Up to $600,000 for a one-year project, with the possibility of follow-on funding based on milestone achievement and progress. - Only direct costs are allowed; indirect costs, capital equipment, and certain other expenses are not permitted. --- ## Eligibility - Open to researchers and clinicians worldwide. - Eligible organizations: - Academic medical centers, universities, and nonprofits. - Biotechnology companies (existing or startups). - Industry partnerships are encouraged. - Funding is provided through a mission-related investment model, which may require a return on investment based on scientific and/or business milestones. --- ## Application Process 1. **Letter of Intent (LOI):** - Submit via the [ADDF Funding Portal](https://addf.fluxx.io/). - Requires brief project summary, specific aims, and supporting data. - One LOI per applicant per cycle; biotech companies may submit one LOI and one full proposal per cycle. - Notification of LOI outcome within 2–3 weeks of the deadline. 2. **Full Proposal:** - By invitation only after LOI approval. - Submit through the same portal. - Must be submitted in the same cycle as the LOI. - Requires detailed scientific narrative, milestones, budget, biosketches, and (for biotech) a business packet. - Notification of funding decision typically within 3–4 months of full proposal submission. 3. **Review Process:** - Proposals are peer-reviewed by scientific and business experts. - Evaluation criteria include scientific merit, innovation, feasibility, team expertise, and translational/commercial potential. --- ## Additional Information - Only direct costs are funded (e.g., personnel, supplies, small equipment, consultants, patient costs for trials). - Indirect costs, capital equipment, publication costs, and travel (except in special cases) are not funded. - Projects must articulate the biomarker’s context of use, comparative advantages, and potential for clinical/commercial translation. - Follow-on funding may be available; contact ADDF staff before the end of the funding period to discuss. --- ## External Links - [Program Page & RFP Details](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers) - [Application Instructions](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/application-instructions) - [Funding Policies](https://www.alzdiscovery.org/research-and-grants/funding-opportunities/policies) - [ADDF Funding Portal (Apply)](https://addf.fluxx.io/) - [ADDF Research Strategy](https://www.alzdiscovery.org/research-and-grants/our-research-strategy) --- ## Contact Information | Contact | Email | Phone | Web Form/Link | |------------------------|------------------------------|----------------|--------------------------------------------------------| | Grants & Investments Team | grants@alzdiscovery.org | 212.901.8000 | [Contact ADDF](https://www.alzdiscovery.org/contact-us) | ---

Biomarkers Development and Validation RFP

Sign in to see full grant listing